HCWB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
135.6K
-97.9%
6.5M
+24124.4%
27.0K
+73.1%
15.6K
+138.3%
6.5K
Cost of Revenue
229.5K
+1972.6%
11.1K
-48.8%
21.6K
+73.1%
12.5K
+138.3%
5.2K
Gross Profit
-93887
-101.4%
6.5M
+120839.3%
5.4K
+73.1%
3.1K
+138.2%
1.3K
Operating Expenses
3.1M
-6.8%
3.3M
-26.2%
4.5M
+35.6%
3.3M
-4.9%
3.5M
R&D
1.2M
-4.3%
1.3M
-5.6%
1.3M
-5.1%
1.4M
+14.5%
1.2M
SG&A
1.9M
+2.0%
1.8M
-41.0%
3.1M
+64.2%
1.9M
-9.8%
2.1M
Operating Income
-3166289
-197.9%
3.2M
+172.5%
-4461822
-35.5%
-3292126
+5.0%
-3464077
EBITDA
-3039194
-190.0%
3.4M
+179.0%
-4275691
-37.1%
-3118221
+1.7%
-3172161
Net Income
-5219231
-250.3%
3.5M
+382.8%
719.2K
+115.8%
-4554336
-136.3%
-1927730
EPS (Basic)
$-11.58
-621.6%
$2.22
+150.3%
$-4.41
+63.6%
$-12.12
+70.2%
$-40.72
EPS (Diluted)
$-11.58
-621.6%
$2.22
+150.3%
$-4.41
+63.6%
$-12.12
+70.2%
$-40.72
Shares (Diluted)
1.3M
+46.8%
904.3K
+15.0%
786.2K
+108.7%
376.7K
+27.0%
296.7K
HCW Biologics (HCWB) โ€” Financials